Starsource Multitrade

Starsource Multitrade CROIC

Rahavoo tootlus investeeritud kapitalile (CROIC) ettevõttest Starsource Multitrade (506365.BO) seisuga 18. okt 2026 on −823,60 %. Eelmisel aastal oli Rahavoo tootlus investeeritud kapitalile (CROIC) −2,15 % — muutus 38 228,46% (madalam).

CROIC

−823,60 %

YoY

38 228,46%

Viimati uuendatud:

Rahavoo tootlus investeeritud kapitalile (CROIC) ettevõttest Starsource Multitrade on 2026 −823,60 % . Rahavoo tootlus investeeritud kapitalile (CROIC) ettevõttest Starsource Multitrade oli 2025 −2,15 % . See väheneb 38 228,46% madalam võrreldes eelmise aastaga.

Starsource Multitrade CROIC ajalugu

  • 3 aastat

  • 10 aastat

  • 25 aastat

  • Max

CROIC
Kuupäev
CROIC
1. jaan 2019
−7,86 INR
1. jaan 2020
44,97 INR
1. jaan 2021
−3,71 INR
1. jaan 2022
−2,84 INR
1. jaan 2023
−5,89 INR
1. jaan 2024
5,65 INR
1. jaan 2025
−2,15 INR
1. jaan 2026
−823,60 INR
Starsource Multitrade CROIC ajalugu
AASTACROICYoY
−823,60 %+38 228,46%
−2,15 %−138,02%
5,65 %−195,95%
−5,89 %+107,16%
−2,84 %−23,43%
−3,71 %−108,26%
44,97 %−671,91%
−7,86 %−52,08%
−16,41 %−125,66%
63,96 %−212,32%
−56,94 %+5610,72%
−1,00 %−70,79%
−3,41 %—

Hangi need andmed Eulerpool API kaudu

100 000 päringut/kuus tasuta · krediitkaarti pole

Starsource Multitrade Aktsiate analüüs

Mida Starsource Multitrade teeb? Starsource Multitrade Ltd, identified by the ticker symbol 506365.BO and ISIN INE320M01019, is a corporate entity registered in India with its headquarters located in Mumbai, Maharashtra. The company was originally established through an initial public offering on January 2, 1995. While the specific sector and industry classifications are currently listed as not applicable, the company's operational history and strategic direction are closely tied to its former identity as Chemo Pharma Laboratories Ltd. This previous incarnation operated within the pharmaceutical industry, focusing on the development and distribution of healthcare products. However, the corporate landscape has shifted significantly, and the entity is no longer engaged in its original pharmaceutical activities. According to available information, the firm currently has no active operations within its traditional business lines. Instead, the organization is in a transitional phase, actively exploring new business opportunities to redefine its market presence. The strategic intent of the current management is to pivot away from pharmaceuticals and acquire businesses in the power and chemicals sectors. This move represents a substantial change in the company's core focus, aiming to diversify its portfolio and enter entirely different industrial segments. The company's official website, https://www.thechemopharmalaboratoriesltd.com/, reflects its historical branding, although the operational reality has evolved. Investors and stakeholders monitoring the company should note that the absence of current operations means that recent financial performance may not reflect traditional revenue streams associated with pharmaceutical manufacturing or sales. The focus is currently on strategic acquisitions and business development rather than organic growth from existing products. The transition from a pharmaceutical manufacturer to a holding or investment vehicle targeting power and chemical assets suggests a long-term restructuring plan. Until new acquisitions are finalized and integrated, the company remains in a state of exploration and preparation. The headquarters in Mumbai serves as the administrative center for these strategic discussions and future operational planning. The lack of a defined sector classification further underscores the company's current status as an entity in flux, waiting for new business units to be acquired and operationalized. This profile highlights the significant shift from its historical roots in healthcare to its current ambitions in energy and industrial chemicals, marking a distinct chapter in the company's corporate evolution. Starsource Multitrade on üks populaarsemaid ettevõtteid Eulpoolist.

Sageli esitatud küsimused Starsource Multitrade aktsia kohta

Starsource Multitrade Rahavoo tootlus investeeritud kapitalile (CROIC) on 2026. aastal −823,60 %.

Rahavoo tootlus investeeritud kapitalile (CROIC) ettevõttest Starsource Multitrade muutus −2,15 % -st −823,60 % -ks, mis vastab 38 228,46% muutusele. Väärtus on madalam kui eelmisel aastal.

Eulpoolist leiate Rahavoo tootlus investeeritud kapitalile (CROIC) Starsource Multitrade täieliku ajaloolise arengu alates 2006. aastast – koos aastate väärtustega, graafikutega ja üksikasjalike analüüsidega.

CROIC mõõdab investeeritud kapitali pealt genereeritud rahavoo tootlust. Erinevalt ROIC-st kasutab see vaba rahavoogu raamatupidamise kasumi asemel, pakkudes puhtamalt kasumlikkuse mõõtu.

Hea väärtus varieerub tööstuse ja ettevõtte arenguetapi järgi. Eulpoolis saate Rahavoo tootlus investeeritud kapitalile (CROIC) Starsource Multitrade võrrelda sektori konkurentidega ja tööstuse keskmisega, et hinnata selle atraktiivsust.

Rahavoo tootlus investeeritud kapitalile (CROIC) hindamiseks on oluline võrrelda seda sama tööstuse ja sektori ettevõtetega. Eulpoolis leiate Rahavoo tootlus investeeritud kapitalile (CROIC) jaoks otsesed tööstusesisesed võrdlused.

Hangi need andmed Eulerpool API kaudu

100 000 päringut/kuus tasuta · krediitkaarti pole

Kasumlikkus — Starsource Multitrade

Kõik finantsnäitajad — Starsource Multitrade